By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...

AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer ...

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter ...

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to report solid second-quarter results later this month, though it sees ...

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...

AstraZeneca pays $600M for global rights to Dizal’s lung cancer drug Zegfrovy, boosting its oncology pipeline.